Price History

Hover for the daily close. The dotted line marks the period open.

Compare AVBP with… →

AVBP Key Statistics

As of Sep 4, 2026

Trading

Open: $30.79
Previous Close: $31.03
Day's Range: 30.60–31.45
52-Week Range: 17.00–35.83
Volume: 182.40K
Beta: 1.36

Valuation

Market Cap: $1.53B
P/E Ratio: unprofitable
EPS (ttm): −3.54

Financials (FY)

Revenue (FY): $0.00
Net Income (FY): −$166.31M
Profit margin: 0.00%
Shares Outstanding: 49.31M
1-Year Return: +58.56%

Dividend and dates

Earnings Date: November 16, 2026estimated
Avg Volume: 517.52K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

AVBP Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

+33.20%−24.47%+53.83%

202420252026*

Year	Return
2026 (partial year)	+53.83%
2025	−24.47%
2024	+33.20%

As of September 4, 2026.

AVBP Revenue and Earnings by Fiscal Year

FY ends December

RevenueNet income

2022202320242025

Fiscal year	Revenue	Net income	Net margin
2025	$0.00	−$166.31M	—
2024	$0.00	−$80.49M	—
2023	$0.00	−$69.33M	—
2022	$0.00	−$36.91M	—

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$0.00	—	−$177.53M	−$166.31M	—
2024	$0.00	—	−$94.31M	−$80.49M	—
2023	$0.00	—	−$74.59M	−$69.33M	—
2022	$0.00	—	−$36.91M	−$36.91M	—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

AVBP Valuation vs Biotechnology Median

Median of 656 stocks

Metric	AVBP	Biotechnology median	vs median
Profit margin	0.00%	0.00%	0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

ArriVent BioPharma, Inc. (AVBP) carries a market capitalisation of $1.53B. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 77.

The 52-week range on file runs from $17.00 to $35.83. AVBP last closed at $30.95 on September 4, 2026. That is −$0.08 (−0.26%) against the previous close. The latest close sits 82.06% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. The same year closed with a net loss of $166.31M. Profit margin runs at 0%. Earnings per share on a trailing basis come to −3.54.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

Beta against the wider market is reported at 1.36. Daily returns over the trailing 2 years annualize to a volatility of 55.28%. Over the trailing twelve months the price has returned +58.56%. The stored price history starts on January 26, 2024, and the total return since then is +54.75%.

Growth & Income

The record shows no dividend for AVBP.

2026 is still running; the price is +53.83% year to date. The strongest complete calendar year on file is 2024 at +33.20%; the weakest is 2025 at −24.47%.

Peer Comparison

ArriVent BioPharma, Inc. (AVBP) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
ArriVent BioPharma, Inc.	AVBP	$1.53B	—
Vertex Pharmaceuticals Incorporated	VRTX	$138.42B	32.5
Regeneron Pharmaceuticals, Inc.	REGN	$85.22B	20.5
argenx SE	ARGX	$64.25B	40.1

The Biotechnology industry average P/E ratio is 12.6x. ArriVent BioPharma, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

ARGX

argenx SE

$64.25B

MRNA

Moderna, Inc.

$58.11B

RVMD

Revolution Medicines, Inc.

$45.01B

ONC

BeOne Medicines AG

$40.53B

View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

JNJ

Johnson & Johnson

$663.28B

ABBV

AbbVie Inc.

$453.19B

MRK

Merck & Co., Inc.

$370.89B

UNH

UnitedHealth Group Incorporated

$356.47B

View all Healthcare stocks →

About ArriVent BioPharma, Inc.

ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company's lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients. It is also developing ARR-217, an antibody drug conjugate (ADC) for the treatment of gastrointestinal cancers; and ARR-002, ARR-421, and ARR-173 for solid tumors. The company has strategic collaborations with Aarvik Therapeutics Inc., Shanghai Allist Pharmaceuticals Co., Ltd., Beijing InnoCare Pharma Tech Co., Ltd., Jiangsu Alphamab Biopharmaceuticals Co., Ltd., and Lepu Biopharma Co. Ltd. ArriVent BioPharma, Inc. was incorporated in 2021 and is based in Newtown Square, Pennsylvania.

Visit website →

ArriVent BioPharma, Inc. (AVBP) Stock Analysis